特一药业（002728）8月25日主力资金净流出2267.04万元

Group 1 - The core viewpoint of the news is that Te Yi Pharmaceutical (002728) has shown significant growth in its financial performance, with a notable increase in revenue and net profit in the latest half-year report [1] - As of August 25, 2025, Te Yi Pharmaceutical's stock closed at 9.44 yuan, down 0.63%, with a trading volume of 287,500 hands and a transaction amount of 271 million yuan [1] - The company's total revenue for the first half of 2025 was 491 million yuan, representing a year-on-year growth of 56.54%, while the net profit attributable to shareholders was 38.01 million yuan, up 1313.23% [1] Group 2 - The company has a current ratio of 1.763, a quick ratio of 1.145, and a debt-to-asset ratio of 22.04%, indicating a strong liquidity position and low leverage [1] - Te Yi Pharmaceutical has made investments in 8 companies and participated in 473 bidding projects, showcasing its active engagement in the market [2] - The company holds 59 trademark registrations and 76 patents, along with 707 administrative licenses, reflecting its commitment to innovation and compliance [2]